The global cardiometabolic drugs market is projected to grow from US$ 50 billion in 2021 to over US$ 70 billion by 2032, with a CAGR of 4% to 5%. Sales are expected to surpass US$ 55 billion by 2022, ...

The use of SGLT2 vs DPP4 inhibitors was linked to reduced cardiovascular and renal risks among patients with comorbid SLE and T2D.

SGLT2 inhibitors may help reduce the risk of nephrolithiasis in patients with type 2 diabetes, including those with co-existing gout. Recent large-scale studies support that sodium-glucose ...

More work is needed to understand how to act preemptively on elevated heart failure risk, one researcher says.

Winters can be uncomfortable for many people, but they can prove life-threatening for those with hypertension if they don't ...

SGLT2 inhibitors plus finerenone may have a protective effect against cardiovascular events in patients with HFpEF or HFmrEF.

Patients at a community health center who had type 2 diabetes and a high risk of atherosclerotic cardiovascular disease (ASCVD) were under-prescribed guideline-recommended treatment with ...

Heart attacks are a leading cause of death and disability in Europe, and their effects often extend beyond the initial event, leading to chronic heart failure.

DelveInsight’s “Congestive Heart Failure Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an ...

From 2021 to 2023, there was an increase in prescription rates of a sodium-glucose cotransporter-2 inhibitor (SGLT2i) for patients with heart failure and a left ventricular ejection fraction (LVEF) ...

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a newer class of medications used to treat type 2 diabetes. These ...